8-K filed Jun 30, 2026 at 08:05 ET
Akebia Therapeutics and U.S. Renal Care announced that the VOICE trial (Vafseo vs. ESA in 2,116 dialysis patients) met its predefined stopping criteria at interim analysis with a win odds of 1.16 (p=0.0016), establishing superiority on the composite endpoint of all-cause mortality and hospitalization. The trial was stopped early based on the recommendation of the Independent Data Monitoring Committee, driven by a statistically significant reduction in hospitalizations (IRR 0.90, p<0.05), with no difference in mortality. This is a strong clinical catalyst, the trial validates Vafseo's safety differentiation over ESAs using a three-times-weekly dosing regimen and directly supports Akebia's commercial positioning in the $306M market cap company's sole marketed product.